[go: up one dir, main page]

AR097087A1 - Derivados de oxoquinazolinil-butanamida - Google Patents

Derivados de oxoquinazolinil-butanamida

Info

Publication number
AR097087A1
AR097087A1 ARP140102799A ARP140102799A AR097087A1 AR 097087 A1 AR097087 A1 AR 097087A1 AR P140102799 A ARP140102799 A AR P140102799A AR P140102799 A ARP140102799 A AR P140102799A AR 097087 A1 AR097087 A1 AR 097087A1
Authority
AR
Argentina
Prior art keywords
denotes
atoms
substituted
het2
replaced
Prior art date
Application number
ARP140102799A
Other languages
English (en)
Inventor
Dr Buchstaller Hans
Peter - Dr Dorsch Dieter
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR097087A1 publication Critical patent/AR097087A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Compuestos de la fórmula (1) en donde Z denota un compuesto seleccionado del grupo de fórmulas (2); X denota CH o N; R¹, R² denotan cada uno, de modo independiente entre sí, H, F o Cl; R³ denota H, F, Cl, CH₃ u OCH₃; R⁴ denota H, F, A, CN, OA o Y; R⁵ denota H, F, A u OA; R⁶ denota CN o 2-pirimidinilo; R⁷ denota Het²; A denota alquilo no ramificado o ramificado con 1 - 8 átomos de C, en donde uno o dos grupos no adyacentes CH y/o CH₂ pueden estar reemplazados por átomos de N u O y en donde 1 - 7 átomos de H pueden estar reemplazados por F, Cl y/u OH; Y denota pirazolilo, que puede estar sustituido con A o (CH₂)ₙHet¹; Het¹ denota pirrolidinilo, piperidinilo, morfolinilo o piperazinilo, cada uno de los cuales puede estar sustituido con A; Het² denota pirazolilo, imidazolilo, oxazolilo, isoxazolilo, pirrolilo, tiazolilo, furanilo o tienilo, cada uno de los cuales puede estar sustituido con A; n es 0, 1, 2, 3 ó 4; y sus sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones.
ARP140102799A 2013-07-31 2014-07-28 Derivados de oxoquinazolinil-butanamida AR097087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13003815 2013-07-31

Publications (1)

Publication Number Publication Date
AR097087A1 true AR097087A1 (es) 2016-02-17

Family

ID=48915813

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102799A AR097087A1 (es) 2013-07-31 2014-07-28 Derivados de oxoquinazolinil-butanamida

Country Status (25)

Country Link
US (1) US9901577B2 (es)
EP (1) EP3027598B1 (es)
JP (1) JP6423875B2 (es)
KR (1) KR102331389B1 (es)
CN (1) CN105392784B (es)
AR (1) AR097087A1 (es)
AU (1) AU2014298955B2 (es)
BR (1) BR112016001645B1 (es)
CA (1) CA2919905C (es)
DK (1) DK3027598T3 (es)
ES (1) ES2632988T3 (es)
HR (1) HRP20171053T1 (es)
HU (1) HUE032846T2 (es)
IL (1) IL243734B (es)
LT (1) LT3027598T (es)
MX (1) MX359656B (es)
NZ (1) NZ716593A (es)
PL (1) PL3027598T3 (es)
PT (1) PT3027598T (es)
RS (1) RS56211B1 (es)
RU (1) RU2669393C2 (es)
SG (1) SG11201600743WA (es)
SI (1) SI3027598T1 (es)
WO (1) WO2015014442A1 (es)
ZA (1) ZA201601333B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016014436A (es) 2014-05-07 2017-01-23 Merck Patent Gmbh Derivados de heterociclil-butanamida.
RU2018119935A (ru) * 2015-11-02 2019-12-04 Мерк Патент Гмбх 1,4-дикарбонилпиперидильные производные
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201615282D0 (en) * 2016-09-08 2016-10-26 Univ Bath Tankyrase inhibitors
PL3562822T3 (pl) 2016-12-30 2021-09-13 Mitobridge, Inc. Inhibitory polimerazy poli(adp-rybozy) (parp)
KR102835667B1 (ko) 2017-12-21 2025-07-21 애브비 바이오테크놀로지 리미티드 Parp14 억제제로서의 퀴나졸리논
CN109180702B (zh) * 2018-10-29 2021-11-30 四川大学 一种噻吩并嘧啶酮化合物及其用途
US20220096454A1 (en) 2018-12-03 2022-03-31 Merck Patent Gmbh Carboxylic acid derivatives
AU2021237690A1 (en) * 2020-03-19 2022-09-08 Merck Patent Gmbh Tetrazole derivatives
EP4384223B1 (en) 2021-08-13 2025-10-01 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023161881A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202915D0 (en) * 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
EP1292313B1 (en) * 2000-05-26 2004-09-08 Idenix (Cayman) Limited Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
BRPI0512790A (pt) 2004-06-30 2008-04-08 Janssen Pharmaceutica Nv derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
CN101492425A (zh) 2009-02-27 2009-07-29 无锡市凯奥善生物医药科技有限公司 一类parp抑制剂的化合物
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9505749B2 (en) * 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof

Also Published As

Publication number Publication date
AU2014298955A1 (en) 2016-03-10
US9901577B2 (en) 2018-02-27
JP6423875B2 (ja) 2018-11-14
MX2016001136A (es) 2016-04-29
BR112016001645B1 (pt) 2023-04-11
SG11201600743WA (en) 2016-02-26
BR112016001645A2 (pt) 2017-08-01
MX359656B (es) 2018-10-05
RS56211B1 (sr) 2017-11-30
RU2016106952A (ru) 2017-09-04
DK3027598T3 (da) 2017-05-22
NZ716593A (en) 2021-07-30
RU2016106952A3 (es) 2018-05-14
IL243734A0 (en) 2016-04-21
ZA201601333B (en) 2019-12-18
LT3027598T (lt) 2017-06-12
CN105392784B (zh) 2018-10-09
HUE032846T2 (en) 2017-11-28
CN105392784A (zh) 2016-03-09
IL243734B (en) 2019-09-26
AU2014298955B2 (en) 2018-03-01
HK1222391A1 (zh) 2017-06-30
JP2016525556A (ja) 2016-08-25
EP3027598A1 (en) 2016-06-08
CA2919905C (en) 2021-08-10
WO2015014442A1 (en) 2015-02-05
PL3027598T3 (pl) 2017-09-29
HRP20171053T1 (hr) 2017-10-06
KR102331389B1 (ko) 2021-11-26
CA2919905A1 (en) 2015-02-05
KR20160037985A (ko) 2016-04-06
PT3027598T (pt) 2017-07-17
SI3027598T1 (sl) 2017-08-31
ES2632988T3 (es) 2017-09-18
RU2669393C2 (ru) 2018-10-11
US20160184310A1 (en) 2016-06-30
EP3027598B1 (en) 2017-04-12
BR112016001645A8 (pt) 2020-01-21

Similar Documents

Publication Publication Date Title
AR097087A1 (es) Derivados de oxoquinazolinil-butanamida
AR092365A1 (es) Derivados de piridopirimidina
AR096235A1 (es) Arilquinazolinas
AR092670A1 (es) Derivados de quinazolinona
AR092211A1 (es) Derivados de hidropirrolopirrol
ES2587953T3 (es) Amidas cíclicas como inhibidores de MetAP-2
AR090103A1 (es) Derivados ciclicos de diaminopirimidina
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR093143A1 (es) Compuestos de 2-aminopiridina
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR091272A1 (es) Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR100333A1 (es) Derivados de heterociclil-butanamida
AR090240A1 (es) Derivados de triazolopirazina
AR092366A1 (es) Derivados de (aza-)isoquinolinona
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
AR097866A1 (es) Derivados de 4-azaindol
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR097086A1 (es) Derivados 1,3-disustituidos de ciclopentano

Legal Events

Date Code Title Description
FG Grant, registration